The holiday season is just around the corner, and we invite you to kick it off with us one week from today on Giving Tuesday (Dec 3)!
Giving Tuesday is a global day of giving back. On the Tuesday following Thanksgiving, you’ll have the chance to join people around the world and support a cause close to your heart.
This Giving Tuesday – and throughout December – the Myeloma Crowd has a goal to raise $250,000 for three multiple myeloma research projects. We invite our incredible supporters like you to join the movement and help us fund cutting-edge research that could lead to a cure for multiple myeloma cancer!
We are also excited to announce that a generous donor has stepped up to match our goal of $250,000 if we can raise an equal amount by December 31 – meaning your donation can have twice the impact!
Donate today or mark your calendars for next Tuesday and help millions around the world make a difference.
MCRI RESEARCH PROJECTS
David Chung, MD, PhD
Memorial Sloan Kettering Cancer Center
Creating an Immune System Signature
Why do some multiple myeloma patients relapse early after stem cell transplant while others stay in remission for many years? The patient’s immune system may be a key factor. Dr. Chung’s research will review patients who have undergone stem cell transplant. He will study three different parts of their immune system after transplant – T cells, lymphocytes and myeloid derived suppressor cells (MDSCs) and will compare patients with early vs. late relapse. He will then combine that immune system signature with the myeloma genetics of each patient to understand the impact they have together.
Cesar Rodriguez, MD
Wake Forest University
Testing Your Individual Myeloma Tumor Against Available Myeloma Therapies
Each myeloma patient’s tumor is unique and can change over time. Dr. Rodriguez is using a new 3D organoid tumor modeling platform which allows the testing of over 50 myeloma treatment combinations against your specific tumor (including your bone marrow microenvironment) to identify which treatments will work best for your type of myeloma. This personalized approach will help you find useful drug combinations that will have the most impact and avoid treatments that will be ineffective.
Fenghuang (Frank) Zhan, PhD
University of Iowa
Targeting CD24 to Eliminate Myeloma Stem Cells
Myeloma stem cells (or early progenitor cells before they become plasma cells) may not be killed with current myeloma therapies and could be the cause of relapse. Dr. Zhan has identified the presence of CD24 as a strong candidate as a cancer stem cell marker and believes that high CD24 levels lead to more aggressive myeloma and earlier death. His work will test patient samples for the presence of CD24 and assess outcomes while also identifying CD24 monoclonal antibodies that could impact this target.
Please invite your caregivers, family and friends to donate on #GivingTuesday to the MCRI to fund these important projects. With the link below, you can donate or create individual or team pages that you can then share with your friends on social media. We need your help because we “Can’t Wait for a Cure.”
The Myeloma Crowd is a 501(c)3 non-profit organization. Donate online or mail donations to the Myeloma Crowd, PO Box 1286, Draper, UT 84020.
Tax ID # 45-5354811